|
|||||
|
|
Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques |
|
| Authors: | Yvonne J Rosenberg David C Montefiori Celia C LaBranche Mark G Lewis Markus Sack Jonathan P Lees Xiaoming Jiang |
| Institution: | 1. PlantVax Corporation, Rockville, Maryland, 20850, United States of America;2. Department of Surgery, Duke University Medical Center, Durham, North Carolina, 27710, United States of America;3. Bioqual Inc., Rockville, Maryland, 20850, United States of America;4. Institute of Molecular Biotechnology, RWTH Aachen University, 52056, Aachen, Germany;Centers for Disease Control and Prevention, UNITED STATES |
| Abstract: | Intravascular delivery of broadly neutralizing antibodies (bnAbs) has shown promise for prevention and treatment of HIV infection. However, multiple IV administrations in geographic locations with poor accessibility to medical care have practical limitations. We have assessed the efficacy of plant-derived PGT121 delivered subcutaneously (SC) against pre-and post-intravaginal challenge using a rigorous SHIV-SF162P3 macaque protection model. SC administered PGT121 exhibited a longer serum half-life than IV administration and was more consistent than intramuscular delivery. A dose of 3.5mg/kg PGT121 prevented infection at a minimum ID50 neutralization titer of 1:295 while 5mg/kg protected five of six macaques when delivered immediately post-challenge. These results suggest the utility of plant-derived bnAbs delivered SC for HIV prevention. |
| Keywords: | |